Superoxide dismutase: Possible therapeutic use in cardiovascular disease

Superoxide dismutase (SOD) for parenteral administration is in clinical use in several european countries, where it is prescribed principally for treatment of musculoskeletal inflammation, especially osteoarthritis [1]. However, new possibilities for its usefulness are arising from recent progresses of the pathophysiology of several diseases. From the beginning of this decade there has been a virtual explosion of the available informations about the mechanisms and control of free radical-mediated tissue injury. This progress has led us to the threshold of what will probably be broad clinical applications in the next future. Taking into account the mortality and morbidity caused by cardiovascular injury, the most promising application of SOD in human therapy seems to relay in the protection against ischaemia and post-ischaemic reperfusion damage of various organs and tissues but, particularly, of the myocardium [2–4]. A large body of evidence suggests that myocardial damage following both global or regional ischaemia can be ameliorated by the blockade of free radical mediated injury [5–7]. SOD has been proposed as a protective agent in various experimental models. The premises of this action, and the available results will be reviewed.